ELP-dependent expression of MCL1 promotes resistance to EGFR inhibition in triple-negative breast cancer cells

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625 · see citing works

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950 · see citing works

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · see citing works

Genome-scale CRISPR-Cas9 knockout screening in human cells

Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234 · see citing works

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499 · see citing works

MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens

Li, W., Xu, H., Xiao, T., Cong, L., Love, M. I., Zhang, F., Irizarry, R. A., Liu, J. S., Brown, M., & Liu, X. S. (2014) · Genome Biology · doi:10.1186/s13059-014-0554-4 · Cited by 2,684 · see citing works

Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma

Nielsen, T. O., Hsu, F. D., Jensen, K. C., Cheang, M. C. U., Karaca, G., Hu, Z., Hernandez‐Boussard, T., Livasy, C., Cowan, D., Dressler, L. G., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0220 · Cited by 2,665 · see citing works

Principles of cancer therapy: oncogene and non-oncogene addiction

Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765 · see citing works

Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways

Sordella, R., Bell, D. W., Haber, D. A., & Settleman, J. E. (2004) · Science · doi:10.1126/science.1101637 · Cited by 1,605 · see citing works

High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.

Hart, T., Chandrashekhar, M., Aregger, M., Steinhart, Z., Brown, K. R., MacLeod, G., Mis, M., Zimmermann, M., Fradet-Turcotte, A., Sun, S., et al. (2015) · Cell · doi:10.1016/j.cell.2015.11.015 · Cited by 1,571 · see citing works

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., et al. (2012) · Nature · doi:10.1038/nature11249 · Cited by 1,134 · see citing works

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

Kotschy, A., Szlavik, Z., Murray, J., Davidson, J., Maragno, A. L., Le Toumelin-Braizat, G., Chanrion, M., Kelly, G. L., Gong, J.-N., Moujalled, D. M., et al. (2016) · Nature · doi:10.1038/nature19830 · Cited by 1,047 · see citing works

EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of <i>BRAF</i> -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

Corcoran, R. B., Ebi, H., Turke, A. B., Coffee, E. M., Nishino, M., Cogdill, A. P., Brown, R. D., Della Pelle, P., Dias-Santagata, D., Hung, K. E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0341 · Cited by 1,022 · see citing works

MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2.

Kozopas, K. M., Yang, T., Buchan, H. L., Zhou, P., & Craig, R. W. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3516 · Cited by 964 · see citing works

Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs

Hafner, M., Niepel, M., Chung, M., & Sorger, P. K. (2016) · Nature Methods · doi:10.1038/nmeth.3853 · Cited by 681 · see citing works

Optimization of Codon Translation Rates via tRNA Modifications Maintains Proteome Integrity

Nedialkova, D. D., & Leidel, S. A. (2015) · Cell · doi:10.1016/j.cell.2015.05.022 · Cited by 546 · see citing works

Highly parallel identification of essential genes in cancer cells

Luo, B., Cheung, H. W., Subramanian, A., Sharifnia, T., Okamoto, M., Yang, X., Hinkle, G., Boehm, J. S., Beroukhim, R., Weir, B. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810485105 · Cited by 541 · see citing works

Current approaches in treatment of triple-negative breast cancer.

Wahba, H. A., & El-Hadaad, H. A. (2015) · Europe PMC (PubMed Central) · doi:10.7497/j.issn.2095-3941.2015.0030 · Cited by 540 · see citing works

TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer

Carey, L. A., Rugo, H. S., Marcom, P. K., Mayer, E. L., Esteva, F. J., Ma, C. X., Liu, M. C., Storniolo, A. M., Rimawi, M. F., Forero-Torres, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.5579 · Cited by 499 · see citing works

Elongator, a Multisubunit Component of a Novel RNA Polymerase II Holoenzyme for Transcriptional Elongation

Otero, G., Fellows, J., Li, Y., de Bizemont, T., Dirac, A. M. G., Gustafsson, C. M., Erdjument‐Bromage, H., Tempst, P., & Svejstrup, J. Q. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80179-3 · Cited by 482 · see citing works

Oncogene addiction: setting the stage for molecularly targeted cancer therapyPreprint

Sharma, S. V., & Settleman, J. E. (2007) · Genes & Development · doi:10.1101/gad.1609907 · Cited by 442 · see citing works

A Genome-wide CRISPR Screen in Primary Immune Cells to Dissect Regulatory Networks

Parnas, O., Jovanovic, M., Eisenhaure, T. M., Herbst, R. H., Dixit, A., Ye, C. J., Przybylski, D., Platt, R. J., Tirosh, I., Sanjana, N. E., et al. (2015) · Cell · doi:10.1016/j.cell.2015.06.059 · Cited by 440 · see citing works

An early step in wobble uridine tRNA modification requires the Elongator complex

Huang, B., Johansson, M., & Byström, A. S. (2005) · RNA · doi:10.1261/rna.7247705 · Cited by 435 · see citing works

The Antiapoptotic Gene <i>mcl-1</i> Is Up-Regulated by the Phosphatidylinositol 3-Kinase/Akt Signaling Pathway through a Transcription Factor Complex Containing CREB

Wang, J.-M., Chao, J.-R., Chen, W., Kuo, M.-L., Yen, J. J.-Y., & Yang-Yen, H.-F. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.9.6195 · Cited by 357 · see citing works

Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer

Corkery, B., Crown, J. P., CLYNES, M. M., & O’Donovan, N. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn710 · Cited by 348 · see citing works

MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol

Domina, A. M., Vrana, J. A., Gregory, M. A., Hann, S. R., & Craig, R. W. (2004) · Oncogene · doi:10.1038/sj.onc.1207692 · Cited by 327 · see citing works

Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation

Ono, M., Hirata, A., Kometani, T., Miyagawa, M., Ueda, S.-I., Kinoshita, H., Fujii, T., & Kuwano, M. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.465.3.4 · Cited by 305 · see citing works

The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2.

Yang, T., Kozopas, K. M., & Craig, R. W. (1995) · The Journal of Cell Biology · doi:10.1083/jcb.128.6.1173 · Cited by 299 · see citing works

BAGEL: a computational framework for identifying essential genes from pooled library screens

Hart, T., & Moffat, J. (2016) · BMC Bioinformatics · doi:10.1186/s12859-016-1015-8 · Cited by 285 · see citing works

Activation of Multiple Proto-oncogenic Tyrosine Kinases in Breast Cancer via Loss of the PTPN12 Phosphatase

Sun, T., Aceto, N., Meerbrey, K. L., Kessler, J. D., Zhou, C., Migliaccio, I., Nguyen, D. X., Pavlova, N. N., Botero, M. F., Huang, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.02.003 · Cited by 277 · see citing works

Repression of Stress-Induced LINE-1 Expression Protects Cancer Cell Subpopulations from Lethal Drug Exposure

Guler, G. D., Tindell, C. A., Pitti, R., Wilson, C., Nichols, K., KaiWai Cheung, T., Kim, H.-J., Wongchenko, M., Yan, Y., Haley, B., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.002 · Cited by 277 · see citing works

Codon-specific translation reprogramming promotes resistance to targeted therapy

Rapino, F., Delaunay, S., Rambow, F., Zhou, Z., Tharun, L., De Tullio, P., Sin, O., Shostak, K., Schmitz, S., Piepers, J., et al. (2018) · Nature · doi:10.1038/s41586-018-0243-7 · Cited by 271 · see citing works

Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure

Pagliarini, R. A., Shao, W., & Sellers, W. R. (2015) · EMBO Reports · doi:10.15252/embr.201439949 · Cited by 255 · see citing works

Identifying chemogenetic interactions from CRISPR screens with drugZ

Colic, M., Wang, G., Zimmermann, M., Mascall, K. S., McLaughlin, M. E., Bertolet, L. L., Lenoir, W. F., Moffat, J., Angers, S., Durocher, D., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0665-3 · Cited by 206 · see citing works

Quantifying drug combination synergy along potency and efficacy axes

Meyer, C. T., Wooten, D. J., Paudel, B. B., Bauer, J., Hardeman, K. N., Westover, D., Lovly, C. M., Harris, L. A., Tyson, D. R., & Quaranta, V. (2019) · Cell Systems · doi:10.1016/j.cels.2019.01.003 · Cited by 202 · see citing works

The conserved Wobble uridine tRNA thiolase Ctu1–Ctu2 is required to maintain genome integrity

Dewez, M., Bauer, F., Dieu, M., Raes, M. J., Vandenhaute, J., & Hermand, D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709404105 · Cited by 155 · see citing works

Human Elongator facilitates RNA polymerase II transcription through chromatin

Kim, J., Lane, W. S., & Reinberg, D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251672198 · Cited by 154 · see citing works

Transcriptional Profiling Identifies Cyclin D1 as a Critical Downstream Effector of Mutant Epidermal Growth Factor Receptor Signaling

Kobayashi, S. S., Shimamura, T., Monti, S., Steidl, U. G., Hetherington, C. J., Lowell, A. M., Golub, T. R., Meyerson, M. M., Tenen, D. G., Shapiro, G. I., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2318 · Cited by 136 · see citing works

Interrogation of Mammalian Protein Complex Structure, Function, and Membership Using Genome-Scale Fitness Screens

Pan, J., Meyers, R. M., Michel, B. C., Mashtalir, N., Sizemore, A. E., Wells, J. N., Cassel, S. H., Vázquez, F., Weir, B. A., Hahn, W. C., et al. (2018) · Cell Systems · doi:10.1016/j.cels.2018.04.011 · Cited by 132 · see citing works

Elongator, a conserved complex required for wobble uridine modifications in Eukaryotes

Karlsborn, T., Tükenmez, H., Mahmud, A. K. M. F., Xu, F., Xu, H., & Byström, A. S. (2014) · RNA Biology · doi:10.4161/15476286.2014.992276 · Cited by 127 · see citing works

Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy.

Weinstein, I. B., Begemann, M., Zhou, P., Han, E. K.-H., Sgambato, A., Doki, Y., Arber, N., Ciaparrone, M., & Yamamoto, H. (1997) · PubMed · Cited by 125 · see citing works

Systematic Quantification of Population Cell Death Kinetics in Mammalian Cells

Forcina, G. C., Conlon, M., Wells, A. C., Cao, J. Y., & Dixon, S. J. (2017) · Cell Systems · doi:10.1016/j.cels.2017.05.002 · Cited by 120 · see citing works

Akt and ERK Control the Proliferative Response of Mammary Epithelial Cells to the Growth Factors IGF-1 and EGF Through the Cell Cycle Inhibitor p57 Kip2

Worster, D. T., Schmelzle, T., Solimini, N. L., Lightcap, E. S., Millard, B. L., Mills, G. B., Brugge, J. S., & Albeck, J. G. (2012) · Science Signaling · doi:10.1126/scisignal.2001986 · Cited by 83 · see citing works

Charting the Fragmented Landscape of Drug Synergy

Meyer, C. T., Wooten, D. J., Lopez, C. F., & Quaranta, V. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.01.011 · Cited by 79 · see citing works

A Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer

Savage, P., Blanchet-Cohen, A., Revil, T., Badescu, D., Saleh, S. M. I., Wang, Y.-C., Zuo, D., Liu, L., Bertos, N., Muñoz-Ramos, V., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.015 · Cited by 73 · see citing works

Additivity of inhibitory effects in multidrug combinations

Russ, D., & Kishony, R. (2018) · Nature Microbiology · doi:10.1038/s41564-018-0252-1 · Cited by 72 · see citing works

Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis

Arai, S., Jonas, O. H., Whitman, M. A., Corey, E., Balk, S. P., & Chen, S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0549 · Cited by 71 · see citing works

gscreend: modelling asymmetric count ratios in CRISPR screens to decrease experiment size and improve phenotype detection

Imkeller, K., Ambrosi, G., Boutros, M., & Huber, W. K. (2020) · Genome biology · doi:10.1186/s13059-020-1939-1 · Cited by 58 · see citing works

Translational offsetting as a mode of estrogen receptor α‐dependent regulation of gene expression

Lorent, J., Kusnadi, E. P., van Hoef, V., Rebello, R. J., Leibovitch, M., Ristau, J., Chen, S., Lawrence, M. G., Szkop, K. J., Samreen, B., et al. (2019) · The EMBO Journal · doi:10.15252/embj.2018101323 · Cited by 46 · see citing works

Estrogen receptor alpha controls gene expression via translational offsetting

Lorent, J., Rebello, R. J., Hoef, V. V., Lawrence, M. G., Szkop, K. J., Kusnadi, E., Samreen, B., Balanathan, P., Scharmann, K., Takizawa, I., et al. (2018) · doi:10.1101/507574 · Cited by 46 · see citing works

Drug antagonism and single-agent dominance result from differences in death kinetics

Richards, R., Schwartz, H. R., Honeywell, M. E., Stewart, M. S., Cruz‐Gordillo, P., Joyce, A. J., Landry, B. D., & Lee, M. J. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0510-4 · Cited by 41 · see citing works

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations

Secq, V., Villeret, J., Fina, F., Carmassi, M., Carcopino, X., Garcia, S., Metellus, I., Boubli, L., Iovanna, J., & Charpin, C. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.794 · Cited by 40 · see citing works

Drug GRADE: An Integrated Analysis of Population Growth and Cell Death Reveals Drug-Specific and Cancer Subtype-Specific Response Profiles

Schwartz, H. R., Richards, R., Fontana, R. E., Joyce, A. J., Honeywell, M. E., & Lee, M. J. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107800 · Cited by 23 · see citing works

Identifying chemogenetic interactions from CRISPR knockout screens with drugZPreprint

Colic, M., Wang, G., Zimmermann, M., Mascall, K., McLaughlin, M., Bertolet, L., Lenoir, W. F., Moffat, J., Angers, S., Durocher, D., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/232736 · Cited by 18 · see citing works

Drug Combination Antagonism and Single Agent Dominance Result from Differences in Death Activation KineticsPreprint

Richards, R., Schwartz, H. R., Stewart, M. S., Cruz‐Gordillo, P., Honeywell, M. E., Joyce, A. J., Landry, B. D., & Lee, M. J. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/805093 · Cited by 4 · see citing works

Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective

Yang, Y., Li, S., Wang, Y., Zhao, Y., & Li, Q. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01168-8 · Cited by 315 · see citing works

Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy

Mukhopadhyay, S., Huang, H.-Y., Lin, Z., Ranieri, M., Li, S., Sahu, S., Liu, Y., Ban, Y., Guidry, K., Hu, H., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-2729 · Cited by 105 · see citing works

Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer

You, K. S., Yi, Y. W., Cho, J., Park, J., & Seong, Y. (2021) · Pharmaceuticals · doi:10.3390/ph14060589 · Cited by 64 · see citing works

Homotypic biomimetic coating synergizes chemo-photothermal combination therapy to treat breast cancer overcoming drug resistance

Guo, K., Liu, Y., Tang, L., & Shubhra, Q. T. H. (2021) · Chemical Engineering Journal · doi:10.1016/j.cej.2021.131120 · Cited by 63 · see citing works

Elp3‐mediated codon‐dependent translation promotes mTORC2 activation and regulates macrophage polarization

Chen, D., Nemazanyy, I., Peulen, O., Shostak, K., Xu, X., Tang, S. C., Wathieu, C., Turchetto, S., Tielens, S., Nguyen, L., et al. (2022) · The EMBO Journal · doi:10.15252/embj.2021109353 · Cited by 45 · see citing works

Trailblazing perspectives on targeting breast cancer stem cells

Li, J., Qi, D., Hsieh, T., Huang, J. H., WU, J. M., & Wu, E. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107800 · Cited by 33 · see citing works

Nanomaterial-assisted CRISPR gene-engineering – A hallmark for triple-negative breast cancer therapeutics advancement

Farheen, J., Hosmane, N. S., Zhao, R., Zhao, Q. D., Iqbal, M. Z., & Kong, X. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100450 · Cited by 28 · see citing works

Role of EGFR and FASN in breast cancer progression

Chaturvedi, S., Biswas, M., Sadhukhan, S., & Sonawane, A. (2023) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-023-00771-w · Cited by 26 · see citing works

Targeting Receptor Tyrosine Kinases as a Novel Strategy for the Treatment of Triple-Negative Breast Cancer

Jaradat, S. K., Ayoub, N. M., Sharie, A. H. A., & Aldaod, J. M. (2024) · Technology in Cancer Research & Treatment · doi:10.1177/15330338241234780 · Cited by 26 · see citing works

Applications of CRISPR Technology to Breast Cancer and Triple Negative Breast Cancer Research

Pont, M., Marqués, M., Sorolla, M. A., Parisi, E., Urdanibia, I., Morales, S. M., Salud, A., & Sorolla, A. (2023) · Cancers · doi:10.3390/cancers15174364 · Cited by 22 · see citing works

Cooperative regulation of coupled oncoprotein synthesis and stability in triple-negative breast cancer by EGFR and CDK12/13

Ang, H. X., Sutiman, N., Deng, X. L., Liu, A., Cerda-Smith, C. G., Hutchinson, H. M., Kim, H., Bartelt, L. C., Chen, Q., Barrera, A., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2221448120 · Cited by 17 · see citing works

Patient-Specific Network for Personalized Breast Cancer Therapy with Multi-Omics Data

Cava, C., Sabetian, S., & Castiglioni, I. (2021) · Entropy · doi:10.3390/e23020225 · Cited by 13 · see citing works

CRISPR/Cas9-mediated silencing of CD44: unveiling the role of hyaluronic acid-mediated interactions in cancer drug resistance

Xu, Z. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02840-8 · Cited by 8 · see citing works

LncRNAs exhibit subtype-specific expression, survival associations, and cancer-promoting effects in breast cancer

Wasson, M. D., Venkatesh, J., Cahill, H. F., McLean, M. E., Dean, C. A., & Marcato, P. (2024) · Gene · doi:10.1016/j.gene.2024.148165 · Cited by 7 · see citing works

CRISPR screening approaches in breast cancer research

Samuels, M. E., Besta, S., Betrán, A. L., Nia, R. S., Xie, X., Gu, X., Shu, Q., & Giamas, G. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10275-1 · Cited by 6 · see citing works

E3 ubiquitin ligase RNF180 reduces sensitivity of triple-negative breast cancer cells to Gefitinib by downregulating RAD51

Liu, P., Zhou, W., Yang, L., & Zhang, C. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.109798 · Cited by 6 · see citing works

Cooperative regulation of coupled oncoprotein translation and stability in triple-negative breast cancer by EGFR and CDK12Preprint

Ang, H. X., Sutiman, N., Deng, X. L., Bartelt, L. C., Chen, Q., Barrera, A., Lin, J., Sheng, J., McDowell, I. C., Reddy, T. E., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.03.433762 · Cited by 2 · see citing works

DR5/WDR12 balances p65 stability promoting sunitinib resistance in renal cell carcinoma

Tao, W., Dong, Y., Zuo, S., Wang, H., Liang, Q., Cai, T., Chen, X. G., Wei, W., Zhang, C., Tian, S., et al. (2026) · Cell Death and Differentiation · doi:10.1038/s41418-026-01723-8 · Cited by 1 · see citing works

Research progress on the application of CRISPR/Cas9 technology in breast cancer treatment

Cai, Y. (2023) · Theoretical and Natural Science · doi:10.54254/2753-8818/20/20230776

Role of ELP6 in tumour progression and impact on ERK1/2 signalling pathway inhibitors in skin cutaneous melanoma

Liu, Y., Wang, Q., Li, Q., & Ren, P. (2025) · Oncology Letters · doi:10.3892/ol.2025.14996

CRISPR-mediated modulation of EGFR signaling in breast cancer

Soleimani, A., & Ghafouri‐Fard, S. (2026) · Gene Reports · doi:10.1016/j.genrep.2026.102432

Genome-wide profiling identifies the genetic dependencies of cell death following EGFR inhibition

Porto, S. A., Birdsall, G. A., Harper, N. W., Honeywell, M. E., Leighow, S. M., Naylor, T. E., Ward, K., Wesley, M. K., Pritchard, J. R., & Lee, M. J. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.111414

Synthetic biology-driven innovations in triple-negative breast cancer: Integrating engineering design with targeted therapeutics

Saliani, N., Hejazi, M. S., Vahed, S. Z., Aghdam, E. M., Mori, Z., Hasheminejad, N., Parvar, M. D., Montazersaheb, S., & Ebrahimi, V. (2026) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2026.04.017

Epigenetic modulation of prostate cancer disparities in men with African ancestry

Craddock, J., & Hayes, V. M. (2026) · Nature Reviews Urology · doi:10.1038/s41585-026-01157-4

Unmasking sensitivity to chemotherapy

Ferrarelli, L. K. (2020) · Science · doi:10.1126/science.370.6519.926-v

Unmasking Oncogene Addiction to the Epidermal Growth Factor Receptor in Triple Negative Breast Cancer: a Lesson in Intrinsic Resistance

Cruz‐Gordillo, P. (2020) · The Journal of the American Medical Association (JAMA) Network (American Medical Association) · doi:10.13028/q4ve-sp89

Abstract LB-219: Nuclear EGFR serves as a functional molecular target in triple-negative breast cancer.

Brand, T. M., Iida, M., Luthar, N., Wleklinski, M. J., Kostopoulos, K. T., & Wheeler, D. L. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-lb-219

Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells

You, K. S., Yi, Y. W., Kwak, S., & Seong, Y. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4244 · Cited by 31 · see citing works

Knockdown of TAZ modifies triple-negative breast cancer cell sensitivity to EGFR inhibitors by regulating YAP expression

Guo, L., Zheng, J., Zhang, J., Wang, H., Shao, G., & Teng, L. (2016) · Oncology Reports · doi:10.3892/or.2016.4875 · Cited by 28 · see citing works